- Home
- HBT vs BLFS Comparison
HBT vs BLFS Comparison
Compare HBT & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | BLFS |
|---|---|---|
| Founded | 1920 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 923.5M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HBT | BLFS |
|---|---|---|
| Price | $28.63 | $25.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $30.75 | ★ $32.00 |
| AVG Volume (30 Days) | 70.9K | ★ 519.2K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 7.96 | ★ 77.27 |
| EPS | ★ 0.34 | 0.02 |
| Revenue | N/A | ★ $96,214,000.00 |
| Revenue This Year | $35.73 | $19.73 |
| Revenue Next Year | $7.01 | $17.82 |
| P/E Ratio | ★ $84.06 | $1,273.75 |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $22.36 | $17.86 |
| 52 Week High | $29.88 | $29.57 |
Technical Indicators
Market Signals| Indicator | HBT | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 66.04 |
| Support Level | $27.15 | $23.74 |
| Resistance Level | $29.14 | $26.39 |
| Average True Range (ATR) | 0.59 | 1.10 |
| MACD | 0.10 | 0.28 |
| Stochastic Oscillator | 76.64 | 87.16 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.